Physician profile
Rachel Eager
NPI 1962093260
$6,628.94
in general payments reported to CMS, 2019-2025
25 companies · $892 in 2025
The $892 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,431 · 2022: $1,818 · 2023: $1,181 · 2024: $1,307 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,718.68 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $547.84 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $537.00 | 2021-2024 | Jornay Pm |
| Lundbeck LLC | $509.28 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $441.10 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $376.20 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $323.20 | 2021-2025 | Caplyta |
| Corium, LLC | $314.88 | 2022-2025 | Azstarys |
| Tris Pharma INC | $280.49 | 2021-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $221.41 | 2021-2024 | Fanapt, Hetlioz |
| Alkermes, INC. | $208.72 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $193.77 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $190.97 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $162.00 | 2021-2023 | Spravato |
| Eisai INC. | $99.30 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $98.98 | 2024-2025 | Relexxii |
| Bausch Health US, LLC | $77.85 | 2022-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $77.48 | 2022-2024 | Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $62.84 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $39.18 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $38.63 | 2021 | |
| Noven Therapeutics, LLC | $38.22 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $28.34 | 2022-2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $26.32 | 2025 | Loreev Xr |
| Alfasigma USA, INC. | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Eager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.